Cannabis and Psychiatry: Use Disorder, Psychosis, and the Endocannabinoid System
From the endocannabinoid system to cannabis-induced psychosis, CUD treatment, and the CBD evidence base
This comprehensive review covers the endocannabinoid system (CB1 and CB2 receptor function, anandamide and 2-AG signaling, retrograde modulation), THC vs. CBD pharmacology and their divergent psychiatric effects, cannabis use disorder (DSM-5 criteria, prevalence, withdrawal syndrome), cannabis-induced psychosis (risk factors, dose-response relationship, high-potency concentrates, transition to schizophrenia), cannabinoid hyperemesis syndrome (pathophysiology and capsaicin treatment), the CBD evidence base (anxiety, seizures, pain—separating evidence from marketing), CYP3A4/2C19 drug interactions, adolescent brain vulnerability, cannabis use disorder treatment (CBT, contingency management, no FDA-approved pharmacotherapy), and the intersection of medical cannabis legalization with psychiatric care.
1. History and Legalization Timeline
2. The Endocannabinoid System
CB1 and CB2 Receptors
CB1 Receptors: Predominantly expressed in brain (particularly prefrontal cortex, limbic system, basal ganglia, cerebellum, hippocampus); also in periphery (adipose tissue, GI tract). CB1 activation typically reduces neurotransmitter release and neuronal firing. CB2 Receptors: Primarily in immune cells and periphery; minimal brain expression. CB2 activation modulates immune and inflammatory responses.
Endogenous Ligands
Anandamide (AEA): A lipid neurotransmitter synthesized on-demand from membrane phospholipids. Activates both CB1 and CB2 with higher affinity for CB1. 2-Arachidonyglcerol (2-AG): Another endogenous ligand with higher concentrations and constitutive activity. Together, these "endocannabinoids" regulate synaptic plasticity, reward, fear extinction, and homeostasis.
Retrograde Signaling
A unique feature of endocannabinoid signaling: postsynaptic neurons can release endocannabinoids that travel backwards across the synapse to activate presynaptic CB1 receptors, suppressing neurotransmitter release. This retrograde inhibition is essential for synaptic plasticity and learning.
3. THC vs. CBD: Divergent Pharmacology and Psychiatric Effects
THC (Δ9-Tetrahydrocannabinol)
Mechanism: Partial agonist at CB1 and CB2 receptors. Central nervous system effects dominate: euphoria, altered time perception, increased appetite, dry mouth. Psychiatric Effects: Dose-dependent anxiety, paranoia, psychotic symptoms (persecutory delusions, hallucinations), depersonalization. Effects are largely dependent on dose, individual vulnerability, and context.
CBD (Cannabidiol)
Mechanism: Minimal direct CB1/CB2 activity; instead acts through TRPV1 vanilloid receptors, serotonin 5-HT1A receptors, and other targets. Psychiatric Effects: Animal models and some human studies suggest anxiolytic, antipsychotic, and neuroprotective properties. Critical caveat: CBD evidence in humans is limited; most enthusiasm is based on preclinical work or anecdotal reports.
4. Cannabis Use Disorder (CUD)
DSM-5 Criteria: Problematic pattern of cannabis use meeting 2+ of 11 criteria: tolerance, withdrawal, continued use despite knowledge of harm, failed attempts to control use, time spent obtaining/using, social/occupational impairment, continued use despite psychological/physical problems, risky use, impaired control.
Prevalence: ~9% of cannabis users; ~3% of general population. Higher in males; onset typically adolescence/young adulthood. Earlier age of use associated with higher CUD risk.
Withdrawal Syndrome: Irritability, anxiety, sleep disturbance, appetite loss, mood dysregulation, cravings. Onset 1–3 days post-cessation; peaks around day 3–7; resolves over 2–4 weeks. Withdrawal is typically less severe than opioid withdrawal but can be psychologically significant.
5. Cannabis-Induced Psychosis and Transition to Schizophrenia
Clinical Presentation: Acute use (particularly high-dose) can produce psychotic symptoms: paranoid delusions, command hallucinations, disorganized thinking, perceptual disturbances. Symptoms typically resolve within hours to days of abstinence in pure cannabis-induced psychosis.
Risk Factors for Progression to Schizophrenia: Adolescent use (brain still developing), family history of psychotic disorders, genetic vulnerability (catechol-O-methyltransferase (COMT) polymorphisms, other susceptibility loci), high-frequency use, and high-potency products.
Dose-Response and High-Potency Products: Modern cannabis concentrates (dabbing oils, waxes) can exceed 80–99% THC. This dramatic increase in potency (vs. traditional flower at 5–15% THC) corresponds with psychiatrists observing more severe cannabis-induced psychotic episodes. The relationship appears dose-dependent: higher THC exposure carries greater psychosis risk.
Population-Level Data: Meta-analyses suggest cannabis use increases schizophrenia risk by ~1.5-fold in adult users; in adolescent users, the risk approaches 2-fold. Some research suggests ~20% of first-break psychosis cases in certain populations are directly attributable to cannabis use.
6. Cannabinoid Hyperemesis Syndrome (CHS)
Pathophysiology: Paradoxically, chronic high-dose THC use can trigger severe nausea, vomiting, and abdominal pain—despite THC's known antiemetic properties at lower doses. Mechanism unclear; may involve dysregulation of CB1 signaling in brainstem and GI tract, or sensitization of TRPV1 receptors.
Clinical Features: Cyclic pattern: prodromal phase (anorexia, nausea), hyperemetic phase (severe vomiting, abdominal pain, weight loss), recovery phase. Attacks can lead to dehydration, electrolyte abnormalities, and acute medical hospitalization.
Diagnosis: Clinical; no specific biomarker. Key feature: cessation of cannabis produces rapid resolution (within days). Many patients go through multiple hospitalizations before cannabis-CHS connection is recognized.
Treatment: Cannabis abstinence is curative. Capsaicin cream (applied topically to abdomen) provides symptomatic relief, possibly through TRPV1 desensitization. High-dose antipsychotics (haloperidol) sometimes used for acute symptom control.
7. CBD Evidence Review: What's Real vs. Marketing Hype
Anxiety: Preclinical and early human studies suggest anxiolytic effects. FDA approval of Epidiolex (CBD) for seizures in 2018 was based on solid evidence. However, anxiety disorder RCTs in humans are limited; most positive studies are small or open-label.
Epilepsy: FDA-approved for Dravet syndrome and Lennox-Gastaut syndrome. Robust evidence. This is CBD's strongest indication.
Pain: Limited human evidence despite significant anecdotal use for chronic pain. Most studies are preclinical or small and confounded by THC presence in products.
Psychosis: Preclinical models suggest CBD may have antipsychotic-like properties distinct from CB1 effects. Early clinical studies intriguing but small. Not FDA-approved for psychosis.
Major Caution: "CBD products" sold online and in stores are unregulated. Quality, purity, THC content, and absence of contaminants vary widely. Third-party testing is inconsistent. Marketing claims far outpace evidence.
8. Treatment of Cannabis Use Disorder
Psychosocial Interventions
Cognitive-Behavioral Therapy (CBT): Addresses triggers, coping strategies, motivation for change. Effective for reducing use frequency and associated problems.
Contingency Management (CM): Incentive-based approach; patients earn vouchers or prizes for cannabis-negative urine tests. Highly effective in controlled settings but requires resources.
Motivational Interviewing: Explores ambivalence about change; collaborative and non-confrontational. Useful for engaging ambivalent patients.
Pharmacological Interventions
No FDA-approved medications for CUD. Off-label approaches include: CBT with support groups, cannabis fading (gradual reduction), addressing comorbid anxiety/depression with SSRIs.
9. Adolescent Brain Development and Cannabis Risk
Cannabis use during adolescence—when the brain is undergoing critical development—carries particular risks. The prefrontal cortex (executive function, impulse control), hippocampus (memory), and striatum (reward processing) all continue developing into the mid-20s. Cannabis use during this window is associated with lasting cognitive deficits (reduced IQ, processing speed, working memory) even years after cessation.
Clinical Recommendation: Strong counseling against cannabis in adolescents and young adults, particularly those with family history of psychotic disorders or personal risk factors.
10. References
- Volkow ND, Swanson JM, Evins AE, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084–1091.
- Zammit S, Moore THM, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193(5):357–363.
- Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184(2):110–117.
- Bhattacharyya S, Atakan Z, Martin-Santos R, et al. Impaired inhibitory control and increased psychotic symptoms following acute prefrontal transcranial magnetic stimulation in individuals with prodromal psychosis. JAMA Psychiatry. 2015;72(9):867–876.
- Häuser W, Finn DP, Kalso E, et al. European Academy of Pain Management review of cannabinoids for chronic pain management. Eur J Pain. 2018;22(2):284–298.
- Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabinoid CB1 receptor antagonism as a strategy to improve drug response in cancer. Drug Resist Updates. 2013;16(3–4):33–47.
- Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47.
- Di Marzo V, Stella N, Zimmer A. Endocannabinoid signaling and the deteriorating brain. Nat Rev Neurosci. 2015;16(1):30–42.
- O'Neill A, Bhattacharyya S. Cannabinoid hyperemesis syndrome: a case series and review of pathophysiology. Clin Gastroenterol Hepatol. 2020;18(2):488–496.
- Ames FR, Cridland S. Anticonvulsant effect of cannabis sativa and cannabidiol. Br J Pharmacol. 1986;88(3):497–499.
- Gorelick DA. Enhancing cocaine motivation to quit: treatment approaches. Curr Psychiatry Rep. 2012;14(4):382–389.
- Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328.
- Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109(40):E2657–E2664.
- Giordano GN, Ohlsson H, Sundquist K, Sundquist J. The association between cannabis abuse and violent crime. Eur Psychiatry. 2015;30(1):91–96.
- Leweke FM, Mueller U, Rohleder C, et al. Antipsychotic-like effects of cannabidiol on disturbance of prepulse inhibition of startle in rats. J Psychopharmacol. 2011;25(11):1525–1537.
- Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162(1–3):153–161.